Stay updated with breaking news from Pleasure Scale. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The device is currently under clinical trial investigation as an adjunct treatment to standard of care therapy for experiential negative symptoms of schizophrenia.
Study investigates the link between stress and autoimmunity, finding a correlation between higher levels of serum and brain-reactive antibodies and depression-like behaviors in mice and humans with Major Depressive Disorder.
Click Therapeutics announced it has enrolled the first patient in a clinical trial of an investigational prescription digital therapeutic to support standard antipsychotic treatment of schizophrenia, according to a company press release.
Mount Sinai Researchers from the Icahn School of Medicine at Mount Sinai have identified a drug that works against depression by a completely different mechanism than existing treatments. Their study showed that ezogabine (also known as retigabine), a drug that opens KCNQ2/3 type of potassium channels in the brain, is associated with significant improvements in depressive symptoms and anhedonia in patients with depression. Anhedonia is the reduced ability to experience pleasure or lack of reactivity to pleasurable stimuli; it is a core symptom of depression and associated with worse outcomes,...